These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37803840)
1. [Efficacy analysis of anti-thymocyte globulin regimens with different timing strategies for matched sibling donor hematopoietic stem cell transplantation]. Du JS; Wang HT; Dou LP; Wang N; Li F; Jin XS; Liu DH Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):660-666. PubMed ID: 37803840 [No Abstract] [Full Text] [Related]
2. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors. Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670 [TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide and horse anti-thymocyte globulin versus fludarabine, reduced cyclophosphamide and rabbit anti-thymocyte globulin conditioning regimen for allogeneic hematopoietic stem cell transplantation from matched sibling donors in patients with acquired aplastic anemia. Ben Abdeljelil N; Ben Yaiche I; Ouerghi R; Torjemane L; Belloumi D; Turki I; Mekni S; Kanoun RY; Ben Othman T; Ladeb S Expert Rev Hematol; 2024 Aug; 17(8):527-538. PubMed ID: 39011776 [TBL] [Abstract][Full Text] [Related]
4. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning. Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820 [TBL] [Abstract][Full Text] [Related]
5. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944 [TBL] [Abstract][Full Text] [Related]
6. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Dou L; Hou C; Ma C; Li F; Gao X; Huang W; Wang S; Gao C; Yu L; Liu D Ann Hematol; 2020 Jan; 99(1):167-179. PubMed ID: 31828376 [TBL] [Abstract][Full Text] [Related]
7. [Application of low-dose ATG for GVHD prophylaxis in patients undergoing PBSCT aged over forty years old]. Liang C; Jiang EL; Yao JF; Ma QL; Zhai WH; Pang AM; Huang Y; Wei JL; Feng SZ; Han MZ Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):292-298. PubMed ID: 29779324 [No Abstract] [Full Text] [Related]
8. Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies. Fang S; Wang N; Wang L; Du J; Yang J; Wen Y; Wei Y; Qian K; Wang H; Jiao Y; Gao C; Dou L Ann Transplant; 2022 Oct; 27():e937356. PubMed ID: 36217289 [TBL] [Abstract][Full Text] [Related]
9. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation. Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377 [TBL] [Abstract][Full Text] [Related]
10. [Single non-blood-related umbilical cord blood transplantation using a reduced-intensity conditioning regimen for the treatment of severe aplastic anemia]. Wu Y; Tang BL; Song KD; Sun GY; Pan TZ; Huang AJ; Yan BB; Zhu XY Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):68-73. PubMed ID: 38527841 [No Abstract] [Full Text] [Related]
11. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
12. Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes. Song ZY; Ren HY; Dong YJ; Li Y; Yin Y; Sun YH; Wang Q; Xu WL; Liu W; Ou JP; Liang ZY Cancer Manag Res; 2020; 12():12287-12300. PubMed ID: 33311999 [TBL] [Abstract][Full Text] [Related]
14. Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment. Woo GU; Hong J; Kim H; Byun JM; Koh Y; Shin DY; Kim I; Yoon SS Biol Blood Marrow Transplant; 2020 Oct; 26(10):1855-1860. PubMed ID: 32561338 [TBL] [Abstract][Full Text] [Related]
15. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421 [TBL] [Abstract][Full Text] [Related]
16. Patients Beyond the Optimal Range of rATG-AUC Still Benefit from the Targeted Dosing Strategy in Unmanipulated Haplo-PBSCT. Du J; Zhang H; Wang H; Luan S; Chen S; Li F; Wang L; Dou L; Liu D Transplant Cell Ther; 2024 Oct; 30(10):1023.e1-1023.e12. PubMed ID: 39111369 [TBL] [Abstract][Full Text] [Related]
17. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG? Weng G; Fan Z; Xue H; Huang F; Xu N; Jin H; Yu S; Ye Z; Fan J; Xuan L; Liu Q Front Immunol; 2022; 13():1036403. PubMed ID: 36389692 [TBL] [Abstract][Full Text] [Related]
18. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418 [TBL] [Abstract][Full Text] [Related]
19. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094 [TBL] [Abstract][Full Text] [Related]
20. Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors. Zhang Y; Chen X; Li L; Li Y; Lin L; Cao Y; Wang N; Yang D; Pang A; Zhang R; Ma Q; Zhai W; He Y; Wei J; Jiang E; Han M; Zhang Y; Feng S Front Immunol; 2022; 13():889784. PubMed ID: 35784311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]